PLX-4720 (Synonyms: Raf Kinase Inhibitor V)

Cell lines

WM793 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

0.5 μM, 96 hours

Applications

Viable cells were identified following 96 h incubation with PLX-4720. Cell viability was further evaluated after re-plating onto non-fibrillar collagen gels, in the continued presence of the drug. Viable cells were identified in ~63% of PLX-4720 treated cultures. These data indicate that melanoma cells harboring a BRAFV600E mutation can survive despite reductions in BRAF activation of the MEK-ERK signaling cascade.

Animal models

Athymic nude mice injected with melanoma A375 cells

Dosage form

Intraperitoneal injection, 25–50mg/kg daily

Applications

PLX-4720 decreased tumor growth as single therapy. When combined with the CRM1 inhibitor KPT-276 (75 mg/kg every day), the two inhibitors induced complete tumor regression per RECIST criteria. The difference between both single therapy and the combination therapy was statistically significant. The effect on apoptosis was believed to be the greatest contribution of the combination since it was significantly increased by the drug combination.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Klein R M, Higgins P J. A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer, 2011, 10: 114.

[2] Fragomeni R A S, Chung H W, Landesman Y, et al. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Molecular cancer therapeutics, 2013, 12(7): 1171-1179.